Future Returns Will Depend On JAK2 Program Validation And Incyte Milestones

Catalysts

About Prelude Therapeutics

Prelude Therapeutics is a clinical stage oncology company focused on discovering and developing precision cancer medicines.

What are the underlying business or industry changes driving this perspective?

• Although the JAK2V617F program addresses a mutation found in more than 200,000 MPN patients in the US, the option agreement gives Incyte up to 18 months to decide whether to buy the asset. This could delay clarity on the program's long term contribution to Prelude's potential revenue and milestone inflows.
• Despite enthusiasm for a mutation selective JAK2 inhibitor, currently approved JAK2 therapies already serve MF and PV. As a result, Prelude may need to show clear disease modifying benefit and manageable anemia and thrombocytopenia to justify premium pricing and broaden use, which could weigh on future revenue if differentiation in clinical data is limited.
• While KAT6A is a clinically validated target in ER positive breast cancer and Prelude's degrader approach aims for strong target engagement, multiple existing treatments and emerging KAT6 agents set a high efficacy and safety bar. Any difficulty replicating preclinical regressions in humans could restrict label scope and cap earnings potential.
• Although the degrader antibody conjugate platform and expanded AbCellera collaboration open the door to licensing opportunities, DACs remain early stage and partner demand and deal economics are uncertain. This may limit the scale and timing of nondilutive capital that flows into operating cash and extends runway.
• While the company highlights cash runway into 2027 and an upfront package of US$60 million from Incyte, INDs for both lead programs are planned around 2026. Any delay in filings, dose escalation or option exercise could increase pressure for additional funding and dilute the impact of potential future revenue, margins and earnings.

Assumptions

This narrative explores a more pessimistic perspective on Prelude Therapeutics compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts. How have these above catalysts been quantified?

• The bearish analysts are assuming Prelude Therapeutics's revenue will grow by 170.7% annually over the next 3 years.
• The bearish analysts assume that profit margins will increase from -1064.5% today to 56.7% in 3 years time.
• The bearish analysts expect earnings to reach $118.2 million (and earnings per share of $0.51) by about March 2029, up from -$111.8 million today. The analysts are largely in agreement about this estimate.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 3.2x on those 2029 earnings, up from -2.3x today. This future PE is lower than the current PE for the US Biotechs industry at 21.2x.
• The bearish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.2%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• If the JAK2V617F selective inhibitor validates a disease modifying approach in a large MPN population of more than 200,000 potential patients in the US, the addressable market and potential future revenue could be higher than you expect, which could put upward pressure on the share price and affect long term revenue and earnings.
• The KAT6A selective degrader targets a clinically validated pathway in ER positive breast cancer, and management is explicitly aiming for best in class style differentiation on both efficacy and safety compared with existing KAT6A/B inhibitors, which, if achieved, could support stronger pricing power, higher usage and upside to long term margins and earnings.
• The exclusive option agreement with Incyte around the JAK2V617F program includes up to US$910 million in potential cash and milestone payments plus royalties, so a positive option exercise or downstream milestones could materially increase non dilutive cash inflows and improve future earnings and valuation multiples.
• The expanded collaboration with AbCellera around degrader antibody conjugates, combined with the broader industry interest in DAC payload licensing, could create additional licensing income and nondilutive capital, which may support a longer cash runway and better long term net margins than you anticipate.
• Management highlights a cash runway into 2027 with two lead programs expected to enter the clinic in 2026, and meaningful early clinical signals in either JAK2V617F or KAT6A could shift investor expectations for long term growth and profitability, which in turn could support a higher share price through improved projected revenue and earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Prelude Therapeutics is $3.0, which represents up to two standard deviations below the consensus price target of $4.0. This valuation is based on what can be assumed as the expectations of Prelude Therapeutics's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $5.0, and the most bearish reporting a price target of just $3.0.
  
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $208.3 million, earnings will come to $118.2 million, and it would be trading on a PE ratio of 3.2x, assuming you use a discount rate of 7.2%.
  
• Given the current share price of $3.12, the analyst price target of $3.0 is 4.0% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.